Brought to you by 
Nanogen reverse merges with Elitech in €66.5mm deal
Sep 2008
Executive Summary
Nanogen has agreed to reverse merge with fellow in vitro diagnostics player Elitech Group (privately held) in a transaction valued at €66.5mm ($99.2mm). The deal excludes Elitech's French sales subsidiary, which the combined entity has the exclusive right to buy for €3.5mm over the next two years.
Deal Industry
-
In Vitro Diagnostics
- Chemistry, Immunoassay
- Hematology, Coagulation
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash
- Includes Contract
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Nanogen reverse merges with Elitech in €66.5mm deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice